The UK continuous glucose monitoring market, valued at $899.846 million in 2030 from $570.921 million in 2025, is projected to grow at a CAGR of 9.53%.
The medical device known as continuous glucose monitoring (CGM) provides ongoing blood sugar observation services to both type 1 and type 2 diabetes patients through wearable apparatus design. A substantial rise in CGM market demand exists across the UK due to numerous market factors.
The increasing number of diabetes patients and enhanced public understanding of CGM devices benefit the market due to government policies and financial support. The market continues to rise because of growing disposable income combined with healthcare having increased prominence in the industry. Other technological observation tools join the CGM device as essential elements that drive modern healthcare. These healthcare devices enable remote patients to use monitoring devices combined with wearable sensors through continuous glucose monitoring systems (CGMS).
Greater use of CGM devices: Adoption of CGM devices among people with diabetes in the UK is on the rise, fueled by heightened awareness of their effectiveness in improving blood glucose control. The National Health Service (NHS) has played a key role in expanding access to these devices, particularly for individuals with type 1 diabetes, often offering them at costs comparable to flash glucose monitors.
The medical device known as continuous glucose monitoring (CGM) provides ongoing blood sugar observation services to both type 1 and type 2 diabetes patients through wearable apparatus design. A substantial rise in CGM market demand exists across the UK due to numerous market factors.
The increasing number of diabetes patients and enhanced public understanding of CGM devices benefit the market due to government policies and financial support. The market continues to rise because of growing disposable income combined with healthcare having increased prominence in the industry. Other technological observation tools join the CGM device as essential elements that drive modern healthcare. These healthcare devices enable remote patients to use monitoring devices combined with wearable sensors through continuous glucose monitoring systems (CGMS).
Greater use of CGM devices: Adoption of CGM devices among people with diabetes in the UK is on the rise, fueled by heightened awareness of their effectiveness in improving blood glucose control. The National Health Service (NHS) has played a key role in expanding access to these devices, particularly for individuals with type 1 diabetes, often offering them at costs comparable to flash glucose monitors.
Why Purchase This Report?
- 70+ pages of actionable data: Pricing trends, units, regional demands, analysis (2023-2030), and competitive benchmarking.
- Proprietary insights: Surveys from industry leaders.
- Excel deliverables: Pre-formatted tables for seamless integration into business strategies.
- Some of the major players covered in this report include Dexcom, Inc., Abbott Laboratories, and Medtronic plc among others.
Key Benefits of this Report:
- Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
- Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
- Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
- Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
- Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive IntelligenceReport Coverage:
- Historical data from 2022 to 2024 & forecast data from 2025 to 2030
- Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
- Competitive Positioning, Strategies, and Market Share Analysis
- Revenue Growth and Forecast Assessment of segments and regions including countries
- Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)
UK Continuous Glucose Monitoring Market Segmentation:
By Gender
- Male
- Female
By Age
- Adults (>14 Years)
- Children (< =14 Years)
By Type
- Real-time CGM
- Intermittent CGM
By Application
- Diabetes Patients
- Critical Care Patients
By End-Users
- Hospitals and Clinics
- Homecare
- Others
Table of Contents
1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
3. BUSINESS LANDSCAPE
4. UK CONTINUOUS GLUCOSE MONITORING MARKET BY GENDER
5. UK CONTINUOUS GLUCOSE MONITORING MARKET BY AGE
6. UK CONTINUOUS GLUCOSE MONITORING MARKET BY TYPE
7. UK CONTINUOUS GLUCOSE MONITORING MARKET BY APPLICATION
8. UK CONTINUOUS GLUCOSE MONITORING MARKET BY END-USERS
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
10. COMPANY PROFILES
11. APPENDIX
Companies Mentioned
- Bottom of FormTop of FormBottom of Form
- Dexcom, Inc.
- Abbott Laboratories
- Medtronic plc
- Roche Diabetes Care, Inc.
- Senseonics Holdings, Inc.
- Ascensia Diabetes Care Holdings AG
- Insulet Corporation
- Tandem Diabetes Care, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 75 |
| Published | April 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 570.92 Million |
| Forecasted Market Value ( USD | $ 899.85 Million |
| Compound Annual Growth Rate | 9.5% |
| Regions Covered | United Kingdom |
| No. of Companies Mentioned | 9 |
